Aliskiren
Spezifikationen
173334-57-1CAS-Nummer
605-672-4EG-Nummer
(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamideIUPAC-Name
C30H53N3O6Chemische Formel
551.8 g/molMolekulargewicht
Aliskiren; 173334-57-1; SPP100; SPP 100; aliskirene; Aliskireno; SPP-100; CGP 60536; 502FWN4Q32; (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide; CHEBI:601027; DTXSID40891494; CGP-060536B; CGP-60536; aliskirenum; (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-((4-methoxy-3-(3-methoxypropoxy)phenyl)methyl)-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonamide; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonamide; RefChem:56248; C09XA02; CGP060536B; DTXCID401030595; CGP60536; Aliskiren(CGP 60536); MFCD09839018; CHEMBL1639; CGP60536B; (2S,4S,5S,7S)-5-AMINO-N-(2-CARBAMOYL-2-METHYLPROPYL)-4-HYDROXY-2-ISOPROPYL-7-[4-METHOXY-3-(3-METHOXYPROPOXY)BENZYL]-8-METHYLNONANAMIDE; (2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide; Benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamide; Benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis-(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-; Aliskiren [INN]; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxo-propyl)-4-hydroxy-2-isopropyl-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-, fumarate; C30H53N3O6; NCGC00186464-01; CGP 60536;CGP60536B;SPP 100; Aliskiren [USAN:INN:BAN]; UNII-502FWN4Q32; Aliskiren?; HSDB 7843; (2S,4S,5S,7S)-5-amino-N-[2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide; Rasilez (TN); Aliskiren (Standard); Aliskiren-hemifumarate; ALISKIREN [MI]; Aliskiren (USAN/INN); ALISKIREN [HSDB]; ALISKIREN [USAN]; ALISKIREN [VANDF]; ALISKIREN [WHO-DD]; ALISKIREN [EMA EPAR]; SCHEMBL455490; GTPL4812; orb1704862; SCHEMBL29521564; BDBM17950; UXOWGYHJODZGMF-QORCZRPOSA-N; GLXC-05705; ALBB-027274; MSK11172; EBC-27307; HY-12176R; STL386835; AKOS015852572; AKOS015888741; CS-0443; DB09026; NCGC00186464-02; NCGC00186464-13; AS-80517; FA134549; HY-12176; SBI-0206888.P001; NS00007787; D03208; EN300-708809; T22233; AB01274865-01; AB01274865_02; AB01274865_03; F793779; Q414904; BRD-K30020243-051-01-7; BRD-K30020243-051-02-5; BRD-K30020243-051-03-3; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl)-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonamide; (2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide; (2s,4s,5s,7s)-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide; 1327153-71-8; 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid hemifumarate; 5(S)-Amino-4(S)-hydroxy-2(S),7(S)-diisopropyl-8-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-octanoic acid N-(2-carbamoyl-2,2-dimethyl-ethyl)-amide; 5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide fumar ate; Benzeneoctanamide, |A-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-|A-hydroxy-4-methoxy-3-(3-methoxypropoxy)-|A,|AE-bis(1-methylethyl)-, (|AS,|AS,|AS,|AES)-; benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-me thylethyl)-, (alphaS,gammaS,deltaS,zetaS)-, fumarate; C41Synonyme
Produkte, die Aliskiren enthalten
RASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULAAliskirenAliskirenAliskiren